AnGes, Inc. (4563.T)
- Previous Close
65.00 - Open
65.00 - Bid 65.00 x --
- Ask 66.00 x --
- Day's Range
64.00 - 66.00 - 52 Week Range
43.00 - 98.00 - Volume
2,214,700 - Avg. Volume
7,353,559 - Market Cap (intraday)
21.259B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-114.38 - Earnings Date Aug 7, 2025 - Aug 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-?B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
www.anges.co.jpRecent News: 4563.T
View MorePerformance Overview: 4563.T
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4563.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4563.T
View MoreValuation Measures
Market Cap
21.26B
Enterprise Value
18.80B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
30.40
Price/Book (mrq)
6.61
Enterprise Value/Revenue
26.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.25%
Return on Equity (ttm)
-194.93%
Revenue (ttm)
699M
Net Income Avi to Common (ttm)
-27.55B
Diluted EPS (ttm)
-114.38
Balance Sheet and Cash Flow
Total Cash (mrq)
2.68B
Total Debt/Equity (mrq)
6.81%
Levered Free Cash Flow (ttm)
--